As such, we are involved in the Marseille immunology biotope
I am the Director of Protisvalor, the research transfer subsidiary of Aix-Marseille University. Protisvalor was founded in 2002 to provide laboratories and researchers with the necessary assistance to valorize their expertise and the results of their research. Since then, we have actively supported the University’s teams in their innovation activities and collaborations with industry and ensure the administrative and financial management of strategic R&D platforms, such as the MI-mAbs pre-industrial demonstrator.
As such, we are involved in the Marseille immunology biotope, so it is natural that today we fully support this initiative.#ecosystem
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.